This article focuses on what clinical research tends to show about the physical changes some people experience after stopping GLP-1 medication particularly weight, appetite, and other body responses documented in trial populations
What are the main drivers shaping demand in the United States health and medical insurance market
In patients with primary or secondary hyperoxaluria, nephrolithiasis, acute or chronic oxalate nephropathy, or chronic kidney disease irrespective of aetiology, one or more of these elements are disrupted
Third, the assumption of comparability across trials may not fully account for differences in adherence, treatment intensification strategies, or background care, which could affect the magnitude of treatment effects
Nelson Medical Anthropology.2017